Abstract:
Objective To explore the effect of Fuke Qianjin Tablets combined with fosfomycin tromethamine in treating patients with chronic pelvic inflammatory disease and its influence on inflammatory factors and quality of sexual life.
Methods A total of 86 chronic pelvic inflammatory disease patients were selected as research objects, and were randomly divided into control group and combined group, with 43 cases in each group. The control group was orally treated with fosfomycin tromethamine powder, and the combined group was given Fuke Qianjin Tablets on the basis of the control group. The treatment of both groups lasted 12 weeks. The therapeutic effects of the two groups were compared, interleukin-1β (IL-1β), interleukin-2 (IL-2), tumor necrosis factor-α (TNF-α), female sexual function index (FSFI) scores and the incidences of adverse reactions of the two groups were compared between the two groups before and after treatment.
Results The total effective rate in the combined group was significantly higher than that of the control group (P<0.05). After treatment, the levels of IL-1β and TNF-α in the two groups were significantly decreased, while the level of IL-2 was significantly increased, and the levels of IL-1β and TNF-α in the combined group were significantly lower than those in the control group, and the level of IL-2 was significantly higher than that in the control group(P<0.05). After treatment, the score of sexual intercourse pain was decreased, the scores of the other five dimensions and total score of FSFI in the two groups were increased compared with those before treatment, and the score of sexual intercourse pain in the combined group was significantly lower, the scores of the other five dimensions and total score of FSFI in the combined group were significantly higher than those in the control group (P<0.05). The incidence of adverse reactions showed no between-group significant difference(P>0.05).
Conclusion Fuke Qianjin Tablets combined with fosfomycin tromethamine has a significant effect on chronic pelvic inflammatory disease patients, which can regulate the level of inflammatory factors, and improve the quality of sexual life.